1
|
Silva AC, Loizou GD, McNally K, Osborne O, Potter C, Gott D, Colbourne JK, Viant MR. A novel method to derive a human safety limit for PFOA by gene expression profiling and modelling. FRONTIERS IN TOXICOLOGY 2024; 6:1368320. [PMID: 38577564 PMCID: PMC10991825 DOI: 10.3389/ftox.2024.1368320] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2024] [Accepted: 03/01/2024] [Indexed: 04/06/2024] Open
Abstract
Perfluorooctanoic acid (PFOA) is a persistent environmental contaminant that can accumulate in the human body due to its long half-life. This substance has been associated with liver, pancreatic, testicular and breast cancers, liver steatosis and endocrine disruption. PFOA is a member of a large group of substances also known as "forever chemicals" and the vast majority of substances of this group lack toxicological data that would enable their effective risk assessment in terms of human health hazards. This study aimed to derive a health-based guidance value for PFOA intake (ng/kg BW/day) from in vitro transcriptomics data. To this end, we developed an in silico workflow comprising five components: (i) sourcing in vitro hepatic transcriptomics concentration-response data; (ii) deriving molecular points of departure using BMDExpress3 and performing pathway analysis using gene set enrichment analysis (GSEA) to identify the most sensitive molecular pathways to PFOA exposure; (iii) estimating freely-dissolved PFOA concentrations in vitro using a mass balance model; (iv) estimating in vivo doses by reverse dosimetry using a PBK model for PFOA as part of a quantitative in vitro to in vivo extrapolation (QIVIVE) algorithm; and (v) calculating a tolerable daily intake (TDI) for PFOA. Fourteen percent of interrogated genes exhibited in vitro concentration-response relationships. GSEA pathway enrichment analysis revealed that "fatty acid metabolism" was the most sensitive pathway to PFOA exposure. In vitro free PFOA concentrations were calculated to be 2.9% of the nominal applied concentrations, and these free concentrations were input into the QIVIVE workflow. Exposure doses for a virtual population of 3,000 individuals were estimated, from which a TDI of 0.15 ng/kg BW/day for PFOA was calculated using the benchmark dose modelling software, PROAST. This TDI is comparable to previously published values of 1.16, 0.69, and 0.86 ng/kg BW/day by the European Food Safety Authority. In conclusion, this study demonstrates the combined utility of an "omics"-derived molecular point of departure and in silico QIVIVE workflow for setting health-based guidance values in anticipation of the acceptance of in vitro concentration-response molecular measurements in chemical risk assessment.
Collapse
Affiliation(s)
- Arthur de Carvalho e Silva
- School of Biosciences, University of Birmingham, Birmingham, United Kingdom
- Centre for Environmental Research and Justice (CERJ), University of Birmingham, Birmingham, United Kingdom
| | | | | | - Olivia Osborne
- Science Evidence and Research Division, Food Standards Agency, London, United Kingdom
| | - Claire Potter
- Science Evidence and Research Division, Food Standards Agency, London, United Kingdom
| | - David Gott
- Science Evidence and Research Division, Food Standards Agency, London, United Kingdom
| | - John K. Colbourne
- School of Biosciences, University of Birmingham, Birmingham, United Kingdom
- Centre for Environmental Research and Justice (CERJ), University of Birmingham, Birmingham, United Kingdom
| | - Mark R. Viant
- School of Biosciences, University of Birmingham, Birmingham, United Kingdom
- Centre for Environmental Research and Justice (CERJ), University of Birmingham, Birmingham, United Kingdom
| |
Collapse
|
2
|
Effective exposure of chemicals in in vitro cell systems: A review of chemical distribution models. Toxicol In Vitro 2021; 73:105133. [DOI: 10.1016/j.tiv.2021.105133] [Citation(s) in RCA: 28] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2020] [Revised: 02/11/2021] [Accepted: 02/25/2021] [Indexed: 12/23/2022]
|
3
|
Pande P, Fleck SC, Twaddle NC, Churchwell MI, Doerge DR, Teeguarden JG. Comparative estrogenicity of endogenous, environmental and dietary estrogens in pregnant women II: Total estrogenicity calculations accounting for competitive protein and receptor binding and potency. Food Chem Toxicol 2018; 125:341-353. [PMID: 30553876 DOI: 10.1016/j.fct.2018.12.013] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2018] [Revised: 11/27/2018] [Accepted: 12/10/2018] [Indexed: 12/22/2022]
Abstract
Evaluating the biological significance of human-relevant exposures to environmental estrogens involves assessing the individual and total estrogenicity of endogenous and exogenous estrogens found in serum, for example from biomonitoring studies. We developed a method for this assessment by integrating approaches for (i) measuring total hormone concentrations by mass spectrometry (Fleck et al., 2018), (ii) calculating hormone bioavailable concentrations in serum and, (iii) solving multiple equilibria between estrogenic ligands and receptors, and (iv) quantitatively describing key elements of estrogen potency. The approach was applied to endogenous (E1, E2, E3, E4), environmental (BPA), and dietary Genistein (GEN), Daidzein (DDZ) estrogens measured in the serum of thirty pregnant women. Fractional receptor occupancy (FRO) based estrogenicity was dominated by E1, E2 and E3 (ER-α, 94.4-99.2% (median: 97.3%), ER-β, 82.7-97.7% (median: 92.8%), as was the total response (TR), which included ligand specific differences in recruitment of co-activator proteins (RCA). The median FRO for BPA was at least five orders of magnitude lower than E1, E2 and E3, and three orders of magnitude lower than the fetal derived E4 and GEN and DDZ. BPA contributed less than 1/1000th of the normal daily variability in total serum estrogenicity in this cohort of pregnant women.
Collapse
Affiliation(s)
- Paritosh Pande
- Health Effects and Exposure Science, Pacific Northwest National Laboratory, Richland, WA, 99352, USA.
| | - Stefanie C Fleck
- Division of Biochemical Toxicology, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, 72079, USA.
| | - Nathan C Twaddle
- Division of Biochemical Toxicology, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, 72079, USA.
| | - Mona I Churchwell
- Division of Biochemical Toxicology, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, 72079, USA.
| | - Daniel R Doerge
- Division of Biochemical Toxicology, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, 72079, USA.
| | - Justin G Teeguarden
- Health Effects and Exposure Science, Pacific Northwest National Laboratory, Richland, WA, 99352, USA; Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR, 93771, USA.
| |
Collapse
|
4
|
Casey WM, Chang X, Allen DG, Ceger PC, Choksi NY, Hsieh JH, Wetmore BA, Ferguson SS, DeVito MJ, Sprankle CS, Kleinstreuer NC. Evaluation and Optimization of Pharmacokinetic Models for in Vitro to in Vivo Extrapolation of Estrogenic Activity for Environmental Chemicals. ENVIRONMENTAL HEALTH PERSPECTIVES 2018; 126:97001. [PMID: 30192161 PMCID: PMC6375436 DOI: 10.1289/ehp1655] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/06/2023]
Abstract
BACKGROUND To effectively incorporate in vitro data into regulatory use, confidence must be established in the quantitative extrapolation of in vitro activity to relevant end points in animals or humans. OBJECTIVE Our goal was to evaluate and optimize in vitro to in vivo extrapolation (IVIVE) approaches using in vitro estrogen receptor (ER) activity to predict estrogenic effects measured in rodent uterotrophic studies. METHODS We evaluated three pharmacokinetic (PK) models with varying complexities to extrapolate in vitro to in vivo dosimetry for a group of 29 ER agonists, using data from validated in vitro [U.S. Environmental Protection Agency (U.S. EPA) ToxCast™ ER model] and in vivo (uterotrophic) methods. In vitro activity values were adjusted using mass-balance equations to estimate intracellular exposure via an enrichment factor (EF), and steady-state model calculations were adjusted using fraction of unbound chemical in the plasma ([Formula: see text]) to approximate bioavailability. Accuracy of each model-adjustment combination was assessed by comparing model predictions with lowest effect levels (LELs) from guideline uterotrophic studies. RESULTS We found little difference in model predictive performance based on complexity or route-specific modifications. Simple adjustments, applied to account for in vitro intracellular exposure (EF) or chemical bioavailability ([Formula: see text]), resulted in significant improvements in the predictive performance of all models. CONCLUSION Computational IVIVE approaches accurately estimate chemical exposure levels that elicit positive responses in the rodent uterotrophic bioassay. The simplest model had the best overall performance for predicting both oral (PPK_EF) and injection (PPK_[Formula: see text]) LELs from guideline uterotrophic studies, is freely available, and can be parameterized entirely using freely available in silico tools. https://doi.org/10.1289/EHP1655.
Collapse
Affiliation(s)
- Warren M Casey
- National Toxicology Program Division, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina, USA
| | - Xiaoqing Chang
- Integrated Laboratory Systems, Inc., Morrisville, North Carolina, USA
| | - David G Allen
- Integrated Laboratory Systems, Inc., Morrisville, North Carolina, USA
| | - Patricia C Ceger
- Integrated Laboratory Systems, Inc., Morrisville, North Carolina, USA
| | - Neepa Y Choksi
- Integrated Laboratory Systems, Inc., Morrisville, North Carolina, USA
| | - Jui-Hua Hsieh
- Kelly Government Solutions, Research Triangle Park, North Carolina, USA
| | | | - Stephen S Ferguson
- National Toxicology Program Division, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina, USA
| | - Michael J DeVito
- National Toxicology Program Division, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina, USA
| | | | - Nicole C Kleinstreuer
- National Toxicology Program Division, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina, USA
| |
Collapse
|
5
|
Liu S, Sun Q. Sex differences, endogenous sex-hormone hormones, sex-hormone binding globulin, and exogenous disruptors in diabetes and related metabolic outcomes. J Diabetes 2018; 10:428-441. [PMID: 27990781 DOI: 10.1111/1753-0407.12517] [Citation(s) in RCA: 38] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/12/2016] [Accepted: 12/13/2016] [Indexed: 12/26/2022] Open
Abstract
In assessing clinical and pathophysiological development of type 2 diabetes (T2D), the critical role of the sex steroids axis is underappreciated, particularly concerning the sex-specific relationships with many relevant cardiometabolic outcomes. In this issue of the Journal of Diabetes, we provide a comprehensive overview of these significant associations of germline variants in the genes governing the sex steroid pathways, plasma levels of steroid hormones, and sex hormone-binding globulin (SHBG) with T2D risk that have been observed in many clinical and high-quality large prospective cohorts of men and women across ethnic populations. Together, this body of evidence indicates that sex steroids and SHBG should be routinely incorporated into clinical characterization of T2D patients, particularly in screening prediabetic patients, such as those with metabolic syndrome, using plasma levels of SHBG. Given that several germline mutations in the SHBG gene have also been directly related to both plasma concentrations of SHBG and clinical manifestation of T2D, targeting signals in the sex steroid axis, particularly SHBG, may have significant utility in the prediction and treatment of T2D. Further, many of the environmental endocrine disrupting chemicals may exert their potential adverse effects on cardiometabolic outcomes via either estrogenic or androgenic signaling pathways, highlighting the importance of using the sex steroids and SHBG as important biochemical markers in both clinical and population studies in studying sex-specific mechanisms in the pathogenesis of T2D and its complications, as well as the need to equitably allocate resources in studying both men and women.
Collapse
Affiliation(s)
- Simin Liu
- Department of Endocrinology, Guangdong General Hospital/Guangdong Academy of Medical Sciences, Guangzhou, China
- Departments of Epidemiology, Brown University, Providence, Rhode Island, USA
- Departments of Medicine, Brown University, Providence, Rhode Island, USA
- Center for Global Cardiometabolic Health, Brown University, Providence, Rhode Island, USA
- Departments of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA
| | - Qi Sun
- Departments of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA
- Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA
| |
Collapse
|
6
|
Poulin P, Arnett R. Integration of a plasma protein binding factor to the Chemical-Specific Adjustment Factor (CSAF) for facilitating the estimation of uncertainties in interspecies extrapolations when deriving health-based exposure limits for active pharmaceutical ingredients: Investigation of recent drug datasets. Regul Toxicol Pharmacol 2017; 91:142-150. [PMID: 29107009 DOI: 10.1016/j.yrtph.2017.10.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2017] [Revised: 10/13/2017] [Accepted: 10/23/2017] [Indexed: 11/30/2022]
Abstract
The objective was to challenge cross-species extrapolation factors with which to scale animal doses to human by any route for non-carcinogenic endpoints. The conventional hypothesis of the toxicokinetics (TK)-toxicodynamics (TD) relationship was equal toxicity at equal plasma level of the total drug moiety in each species, but this should also follow the free drug assumption, which states that only the unbound drug moiety in plasma may elicit a TD effect in tissue. Therefore, a protein binding factor (PBF) was combined with the Chemical-Specific Adjustment Factor (CSAF) (i.e., CSAF x PBF). The value of PBF of each drug was set equal to the ratio between human and animals of the unbound fraction in plasma (fup). Recent drug datasets were investigated. Our results indicate that any CSAF value would be increased or decreased while PBF deviates to the unity, and this required more attention. Accordingly, further testing indicated that the CSAF values set equal to basic allometric uncertainty factors according to the conventional hypothesis (dog∼2, monkey∼3.1, rat∼7, mouse∼12) would increase by including PBF for 30% of the drugs tested that showed a superior fup value in human compared to animals. However, default uncertainty factors in the range of 10-100 were less frequently exceeded. Overall, PBF could be combined with any other uncertainty factor to get reliable estimate of CSAF for each bound drug in deriving health-based exposure limits.
Collapse
Affiliation(s)
- Patrick Poulin
- Consultant Patrick Poulin Inc., Québec City, Québec, Canada; Department of Occupational and Environmental Health, School of Public Health, IRSPUM, Université de Montréal, Québec, Canada.
| | - Richard Arnett
- Industrial Hygiene, Pharmascience Inc., 100, boul. de l'Industrie, Candiac, Québec Canada
| |
Collapse
|
7
|
Graepel R, Lamon L, Asturiol D, Berggren E, Joossens E, Paini A, Prieto P, Whelan M, Worth A. The virtual cell based assay: Current status and future perspectives. Toxicol In Vitro 2017; 45:258-267. [PMID: 28108195 PMCID: PMC5742635 DOI: 10.1016/j.tiv.2017.01.009] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2015] [Revised: 12/15/2016] [Accepted: 01/15/2017] [Indexed: 12/22/2022]
Abstract
In order to replace the use of animals in toxicity testing, there is a need to predict in vivo toxic doses from concentrations that cause toxicological effects in relevant in vitro systems. The Virtual Cell Based Assay (VCBA) estimates time-dependent concentration of a test chemical in the cell and cell culture for a given in vitro system. The concentrations in the different compartments of the cell and test system are derived from ordinary differential equations, physicochemical parameters of the test chemical and properties of the cell line. The VCBA has been developed for a range of cell lines including BALB/c 3T3 cells, HepG2, HepaRG, lung A459 cells, and cardiomyocytes. The model can be used to design and refine in vitro experiments and extrapolate in vitro effective concentrations to in vivo doses that can be applied in risk assessment. In this paper, we first discuss potential applications of the VCBA: i) design of in vitro High Throughput Screening (HTS) experiments; ii) hazard identification (based on acute systemic toxicity); and iii) risk assessment. Further extension of the VCBA is discussed in the second part, exploring potential application to i) manufactured nanomaterials, ii) additional cell lines and endpoints, and considering iii) other opportunities. VCBA as an alternative approach can be applied in the domain of nanotoxicology. VCBA can support better testing strategies in acute toxicity. Refinement of the VCBA taking into account biological oscillators could improve toxicity prediction. Extensions of the VCBA can capture effects related to additional subcellular compartments.
Collapse
Affiliation(s)
- Rabea Graepel
- Chemical Safety and Alternative Methods Unit incorporating EURL ECVAM, Directorate Health, Consumers and Reference Materials, European Commission, Joint Research Centre, Ispra, Italy
| | - Lara Lamon
- Chemical Safety and Alternative Methods Unit incorporating EURL ECVAM, Directorate Health, Consumers and Reference Materials, European Commission, Joint Research Centre, Ispra, Italy.
| | - David Asturiol
- Chemical Safety and Alternative Methods Unit incorporating EURL ECVAM, Directorate Health, Consumers and Reference Materials, European Commission, Joint Research Centre, Ispra, Italy
| | - Elisabet Berggren
- Chemical Safety and Alternative Methods Unit incorporating EURL ECVAM, Directorate Health, Consumers and Reference Materials, European Commission, Joint Research Centre, Ispra, Italy
| | - Elisabeth Joossens
- Chemical Safety and Alternative Methods Unit incorporating EURL ECVAM, Directorate Health, Consumers and Reference Materials, European Commission, Joint Research Centre, Ispra, Italy
| | - Alicia Paini
- Chemical Safety and Alternative Methods Unit incorporating EURL ECVAM, Directorate Health, Consumers and Reference Materials, European Commission, Joint Research Centre, Ispra, Italy
| | - Pilar Prieto
- Chemical Safety and Alternative Methods Unit incorporating EURL ECVAM, Directorate Health, Consumers and Reference Materials, European Commission, Joint Research Centre, Ispra, Italy
| | - Maurice Whelan
- Chemical Safety and Alternative Methods Unit incorporating EURL ECVAM, Directorate Health, Consumers and Reference Materials, European Commission, Joint Research Centre, Ispra, Italy
| | - Andrew Worth
- Chemical Safety and Alternative Methods Unit incorporating EURL ECVAM, Directorate Health, Consumers and Reference Materials, European Commission, Joint Research Centre, Ispra, Italy
| |
Collapse
|
8
|
Riebeling C, Jungnickel H, Luch A, Haase A. Systems Biology to Support Nanomaterial Grouping. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2017; 947:143-171. [PMID: 28168668 DOI: 10.1007/978-3-319-47754-1_6] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
The assessment of potential health risks of engineered nanomaterials (ENMs) is a challenging task due to the high number and great variety of already existing and newly emerging ENMs. Reliable grouping or categorization of ENMs with respect to hazards could help to facilitate prioritization and decision making for regulatory purposes. The development of grouping criteria, however, requires a broad and comprehensive data basis. A promising platform addressing this challenge is the systems biology approach. The different areas of systems biology, most prominently transcriptomics, proteomics and metabolomics, each of which provide a wealth of data that can be used to reveal novel biomarkers and biological pathways involved in the mode-of-action of ENMs. Combining such data with classical toxicological data would enable a more comprehensive understanding and hence might lead to more powerful and reliable prediction models. Physico-chemical data provide crucial information on the ENMs and need to be integrated, too. Overall statistical analysis should reveal robust grouping and categorization criteria and may ultimately help to identify meaningful biomarkers and biological pathways that sufficiently characterize the corresponding ENM subgroups. This chapter aims to give an overview on the different systems biology technologies and their current applications in the field of nanotoxicology, as well as to identify the existing challenges.
Collapse
Affiliation(s)
- Christian Riebeling
- German Federal Institute for Risk Assessment, Department of Chemical and Product Safety, Berlin, Germany
| | - Harald Jungnickel
- German Federal Institute for Risk Assessment, Department of Chemical and Product Safety, Berlin, Germany
| | - Andreas Luch
- German Federal Institute for Risk Assessment, Department of Chemical and Product Safety, Berlin, Germany
| | - Andrea Haase
- German Federal Institute for Risk Assessment, Department of Chemical and Product Safety, Berlin, Germany.
| |
Collapse
|
9
|
Why did researchers not use realistic doses in animal studies of bisphenol A? Arch Toxicol 2016; 91:1519-1522. [DOI: 10.1007/s00204-016-1840-6] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2016] [Accepted: 08/25/2016] [Indexed: 12/19/2022]
|
10
|
Nowicki BA, Hamada MA, Robinson GY, Jones DC. Adverse effects of bisphenol A (BPA) on the dopamine system in two distinct cell models and corpus striatum of the Sprague-Dawley rat. JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH. PART A 2016; 79:912-924. [PMID: 27494678 DOI: 10.1080/15287394.2016.1204577] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/24/2015] [Accepted: 06/18/2016] [Indexed: 06/06/2023]
Abstract
The aim of this study was to examine the effects of bisphenol A (BPA) on the brain dopamine (DA) system utilizing both in vitro models (GH3 cells, a rat pituitary cell line, and SH-SY5Y cells, a human neuroblastoma cell line) and an animal model such as Sprague-Dawley (SD) rats. First, cellular DA uptake was measured 2 or 8 h following BPA exposure (0.1-400 μM) in SH-SY5Y cells, where a significant increase in DA uptake was noted. BPA exerted no marked effect on dopamine active transporter levels in GH3 cells exposed for 8 or 24 h. However, SH-SY5Y cells displayed an increase in dopamine transporter (DAT) levels following 24 h of exposure to BPA. In contrast to DAT levels, BPA exposure produced no marked effect on DA D1 receptor levels in SH-SY5Y cells, yet a significant decrease in GH3 cells following both 8- and 24-h exposure periods was noted, suggesting that BPA exerts differential effects dependent upon cell type. BPA produced no significant effects on prolactin levels at 2 h, but a marked fall occurred at 24 h of exposure in GH3 cells. Finally, to examine the influence of dietary developmental exposure to BPA on brain DA levels in F1 offspring, SD rats were exposed to BPA (0.5-20 mg/kg) through maternal transfer and/or diet and striatal DA levels were measured on postnatal day (PND) 60 using high-performance liquid chromatography (HPLC). Data demonstrated that chronic exposure to BPA did not significantly alter striatal DA levels in the SD rat.
Collapse
Affiliation(s)
| | - Matt A Hamada
- a AZCOM , Midwestern University , Glendale , AZ , 85308 USA
| | | | | |
Collapse
|
11
|
Urine and serum biomonitoring of exposure to environmental estrogens I: Bisphenol A in pregnant women. Food Chem Toxicol 2016; 92:129-42. [DOI: 10.1016/j.fct.2016.03.023] [Citation(s) in RCA: 44] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2015] [Revised: 03/25/2016] [Accepted: 03/26/2016] [Indexed: 02/02/2023]
|
12
|
Teeguarden JG, Mikheev VB, Minard KR, Forsythe WC, Wang W, Sharma G, Karin N, Tilton SC, Waters KM, Asgharian B, Price OR, Pounds JG, Thrall BD. Comparative iron oxide nanoparticle cellular dosimetry and response in mice by the inhalation and liquid cell culture exposure routes. Part Fibre Toxicol 2014; 11:46. [PMID: 25266609 PMCID: PMC4200214 DOI: 10.1186/s12989-014-0046-4] [Citation(s) in RCA: 45] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2014] [Accepted: 08/25/2014] [Indexed: 11/29/2022] Open
Abstract
Background Toxicity testing the rapidly growing number of nanomaterials requires large scale use of in vitro systems under the presumption that these systems are sufficiently predictive or descriptive of responses in in vivo systems for effective use in hazard ranking. We hypothesized that improved relationships between in vitro and in vivo models of experimental toxicology for nanomaterials would result from placing response data in vitro and in vivo on the same dose scale, the amount of material associated with cells. Methods Balb/c mice were exposed nose-only to an aerosol (68.6 nm CMD, 19.9 mg/m3, 4 hours) generated from of 12.8 nm superparamagnetic iron oxide particles (SPIO). Target cell doses were calculated, histological evaluations conducted, and biomarkers of response were identified by global transcriptomics. Representative murine epithelial and macrophage cell types were exposed in vitro to the same material in liquid suspension for four hours and levels of nanoparticle regulated cytokine transcripts identified in vivo were quantified as a function of measured nanoparticle cellular dose. Results Target tissue doses of 0.009-0.4 μg SPIO/cm2 in lung led to an inflammatory response in the alveolar region characterized by interstitial inflammation and macrophage infiltration. In vitro, higher target tissue doses of ~1.2-4 μg SPIO/ cm2 of cells were required to induce transcriptional regulation of markers of inflammation, CXCL2 & CCL3, in C10 lung epithelial cells. Estimated in vivo macrophage SPIO nanoparticle doses ranged from 1-100 pg/cell, and induction of inflammatory markers was observed in vitro in macrophages at doses of 8-35 pg/cell. Conclusions Application of target tissue dosimetry revealed good correspondence between target cell doses triggering inflammatory processes in vitro and in vivo in the alveolar macrophage population, but not in the epithelial cells of the alveolar region. These findings demonstrate the potential for target tissue dosimetry to enable the more quantitative comparison of in vitro and in vivo systems and advance their use for hazard assessment and extrapolation to humans. The mildly inflammogentic cellular doses experienced by mice were similar to those calculated for humans exposed to the same material at the existing permissible exposure limit of 10 mg/m3 iron oxide (as Fe). Electronic supplementary material The online version of this article (doi:10.1186/s12989-014-0046-4) contains supplementary material, which is available to authorized users.
Collapse
|
13
|
Mattison DR, Karyakina N, Goodman M, LaKind JS. Pharmaco- and toxicokinetics of selected exogenous and endogenous estrogens: A review of the data and identification of knowledge gaps. Crit Rev Toxicol 2014; 44:696-724. [DOI: 10.3109/10408444.2014.930813] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
14
|
|
15
|
Churchwell MI, Camacho L, Vanlandingham MM, Twaddle NC, Sepehr E, Delclos KB, Fisher JW, Doerge DR. Comparison of life-stage-dependent internal dosimetry for bisphenol A, ethinyl estradiol, a reference estrogen, and endogenous estradiol to test an estrogenic mode of action in Sprague Dawley rats. Toxicol Sci 2014; 139:4-20. [PMID: 24496641 DOI: 10.1093/toxsci/kfu021] [Citation(s) in RCA: 72] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Bisphenol A (BPA) was administered by gavage (2.5-300,000 μg/kg body weight (bw)/day) to pregnant Sprague Dawley dams, newborn pups, and continuing into adulthood. Aglycone (i.e., unconjugated and active) and conjugated (i.e., inactive) BPA were evaluated by liquid chromatography electrospray tandem mass spectrometry (LC-ES/MS/MS) in serum to better interpret toxicological endpoints measured in the study. Ethinyl estradiol (EE2, 0.5 and 5 μg/kg bw/day) and the endogenous hormones, 17β-estradiol (E2) and testosterone, were similarly evaluated. Mean BPA aglycone levels in vehicle and naïve control rat serum (0.02-0.5 ng/ml) indicated sample processing artifact, consistent with literature reports of a propensity for postexposure blood contamination by BPA. Direct measurements of BPA-glucuronide in vehicle and naïve control serum (2-10nM) indicated unintentional exposure and metabolism at levels similar to those produced by 2.5 μg/kg bw/day BPA (7-10nM), despite careful attention to potential BPA inputs (diet, drinking water, vehicle, cages, bedding, and dust) and rigorous dosing solution certification and delivery. The source of this exposure could not be identified, but interpretation of the toxicological effects, observed only at the highest BPA doses, was not compromised. Internal exposures to BPA and EE2 aglycones were highest in young rats. When maximal serum concentrations from the two highest BPA doses and both EE2 doses were compared with concurrent levels of endogenous E2, the ERα binding equivalents were similar to or above those of endogenous E2 in male and female rats of all ages tested. Such evaluations of estrogenic internal dosimetry and comprehensive evaluation of contamination impact should aid in extrapolating risks from human BPA exposures.
Collapse
Affiliation(s)
- Mona I Churchwell
- U.S. Food and Drug Administration, National Center for Toxicological Research, Division of Biochemical Toxicology, 3900 NCTR Road, Jefferson, Arkansas 72079
| | | | | | | | | | | | | | | |
Collapse
|
16
|
Effect of combining in vitro estrogenicity data with kinetic characteristics of estrogenic compounds on the in vivo predictive value. Toxicol In Vitro 2013; 27:44-51. [DOI: 10.1016/j.tiv.2012.09.014] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2012] [Revised: 09/17/2012] [Accepted: 09/18/2012] [Indexed: 11/23/2022]
|
17
|
Yoon M, Campbell JL, Andersen ME, Clewell HJ. Quantitativein vitrotoin vivoextrapolation of cell-based toxicity assay results. Crit Rev Toxicol 2012; 42:633-52. [DOI: 10.3109/10408444.2012.692115] [Citation(s) in RCA: 162] [Impact Index Per Article: 13.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
18
|
Li Z, Kroll KJ, Jensen KM, Villeneuve DL, Ankley GT, Brian JV, Sepúlveda MS, Orlando EF, Lazorchak JM, Kostich M, Armstrong B, Denslow ND, Watanabe KH. A computational model of the hypothalamic: pituitary: gonadal axis in female fathead minnows (Pimephales promelas) exposed to 17α-ethynylestradiol and 17β-trenbolone. BMC SYSTEMS BIOLOGY 2011; 5:63. [PMID: 21545743 PMCID: PMC3118352 DOI: 10.1186/1752-0509-5-63] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/20/2010] [Accepted: 05/05/2011] [Indexed: 11/10/2022]
Abstract
Background Endocrine disrupting chemicals (e.g., estrogens, androgens and their mimics) are known to affect reproduction in fish. 17α-ethynylestradiol is a synthetic estrogen used in birth control pills. 17β-trenbolone is a relatively stable metabolite of trenbolone acetate, a synthetic androgen used as a growth promoter in livestock. Both 17α-ethynylestradiol and 17β-trenbolone have been found in the aquatic environment and affect fish reproduction. In this study, we developed a physiologically-based computational model for female fathead minnows (FHM, Pimephales promelas), a small fish species used in ecotoxicology, to simulate how estrogens (i.e., 17α-ethynylestradiol) or androgens (i.e., 17β-trenbolone) affect reproductive endpoints such as plasma concentrations of steroid hormones (e.g., 17β-estradiol and testosterone) and vitellogenin (a precursor to egg yolk proteins). Results Using Markov Chain Monte Carlo simulations, the model was calibrated with data from unexposed, 17α-ethynylestradiol-exposed, and 17β-trenbolone-exposed FHMs. Four Markov chains were simulated, and the chains for each calibrated model parameter (26 in total) converged within 20,000 iterations. With the converged parameter values, we evaluated the model's predictive ability by simulating a variety of independent experimental data. The model predictions agreed with the experimental data well. Conclusions The physiologically-based computational model represents the hypothalamic-pituitary-gonadal axis in adult female FHM robustly. The model is useful to estimate how estrogens (e.g., 17α-ethynylestradiol) or androgens (e.g., 17β-trenbolone) affect plasma concentrations of 17β-estradiol, testosterone and vitellogenin, which are important determinants of fecundity in fish.
Collapse
Affiliation(s)
- Zhenhong Li
- Division of Environmental and Biomolecular Systems, Oregon Health & Science University, Beaverton, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Bianco M, Mita L, Portaccio M, Diano N, Sica V, De Luca B, Mita DG, Carratelli CR, Viggiano E. Differential accumulation levels in the brain of rats exposed to the endocrine disruptor 4-tert-octylphenol (OP). ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY 2011; 31:198-204. [PMID: 21787686 DOI: 10.1016/j.etap.2010.10.008] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/03/2010] [Revised: 09/29/2010] [Accepted: 10/28/2010] [Indexed: 05/31/2023]
Abstract
Octylphenol (OP) is an endocrine-disrupting chemical that accumulates in various organs. It has also been shown to exert noxious effects on the central nervous system. In the present study, we measured in Sprague-Dawley rats the degree of OP accumulation in different areas of the brain and investigated the effect of OP in pain modulation. Two groups of male Sprague-Dawley rats were treated for 20 days with 50mg/kg BW/day of OP (group 1) or vehicle (group 2). At the end of the treatment, the formalin test was performed to evaluate the effect of OP exposure on pain. Soon after, rats were sacrificed, and the accumulation of OP in the cerebral cortex, hippocampus, hypothalamus, cerebellum, thalamus, striatum, mesencephalus and ventral hindbrain was measured by HPLC analysis. The results showed a greater accumulation of OP in the cerebral cortex compared to all the other areas; there was also more accumulation in the cerebellum compared to the mesencephalus and thalamus. No accumulation was found in the striatum. These results suggest that there is a preferential accumulation of OP in different areas of the brain with consequences to neural behaviour. On the contrary, experiments on facial grooming did not show significant effects of OP on pain.
Collapse
Affiliation(s)
- M Bianco
- National Institute of Biostructures and Biosystems, Viale Medaglie d'Oro, 305, 00136 Rome, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Hinderliter PM, Minard KR, Orr G, Chrisler WB, Thrall BD, Pounds JG, Teeguarden JG. ISDD: A computational model of particle sedimentation, diffusion and target cell dosimetry for in vitro toxicity studies. Part Fibre Toxicol 2010; 7:36. [PMID: 21118529 PMCID: PMC3012653 DOI: 10.1186/1743-8977-7-36] [Citation(s) in RCA: 330] [Impact Index Per Article: 23.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2010] [Accepted: 11/30/2010] [Indexed: 01/01/2023] Open
Abstract
BACKGROUND The difficulty of directly measuring cellular dose is a significant obstacle to application of target tissue dosimetry for nanoparticle and microparticle toxicity assessment, particularly for in vitro systems. As a consequence, the target tissue paradigm for dosimetry and hazard assessment of nanoparticles has largely been ignored in favor of using metrics of exposure (e.g. μg particle/mL culture medium, particle surface area/mL, particle number/mL). We have developed a computational model of solution particokinetics (sedimentation, diffusion) and dosimetry for non-interacting spherical particles and their agglomerates in monolayer cell culture systems. Particle transport to cells is calculated by simultaneous solution of Stokes Law (sedimentation) and the Stokes-Einstein equation (diffusion). RESULTS The In vitro Sedimentation, Diffusion and Dosimetry model (ISDD) was tested against measured transport rates or cellular doses for multiple sizes of polystyrene spheres (20-1100 nm), 35 nm amorphous silica, and large agglomerates of 30 nm iron oxide particles. Overall, without adjusting any parameters, model predicted cellular doses were in close agreement with the experimental data, differing from as little as 5% to as much as three-fold, but in most cases approximately two-fold, within the limits of the accuracy of the measurement systems. Applying the model, we generalize the effects of particle size, particle density, agglomeration state and agglomerate characteristics on target cell dosimetry in vitro. CONCLUSIONS Our results confirm our hypothesis that for liquid-based in vitro systems, the dose-rates and target cell doses for all particles are not equal; they can vary significantly, in direct contrast to the assumption of dose-equivalency implicit in the use of mass-based media concentrations as metrics of exposure for dose-response assessment. The difference between equivalent nominal media concentration exposures on a μg/mL basis and target cell doses on a particle surface area or number basis can be as high as three to six orders of magnitude. As a consequence, in vitro hazard assessments utilizing mass-based exposure metrics have inherently high errors where particle number or surface areas target cells doses are believed to drive response. The gold standard for particle dosimetry for in vitro nanotoxicology studies should be direct experimental measurement of the cellular content of the studied particle. However, where such measurements are impractical, unfeasible, and before such measurements become common, particle dosimetry models such as ISDD provide a valuable, immediately useful alternative, and eventually, an adjunct to such measurements.
Collapse
Affiliation(s)
- Paul M Hinderliter
- Biological Sciences Division, Pacific Northwest National Laboratory, Richland WA 99352, USA
| | | | | | | | | | | | | |
Collapse
|
21
|
Marty MS, Carney EW, Rowlands JC. Endocrine Disruption: Historical Perspectives and Its Impact on the Future of Toxicology Testing. Toxicol Sci 2010; 120 Suppl 1:S93-108. [DOI: 10.1093/toxsci/kfq329] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
22
|
Hamelin G, Haddad S, Krishnan K, Tardif R. Physiologically based modeling of p-tert-octylphenol kinetics following intravenous, oral or subcutaneous exposure in male and female Sprague-Dawley rats. J Appl Toxicol 2010; 30:437-49. [PMID: 20186885 DOI: 10.1002/jat.1515] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
The objective of this study was to develop a physiologically based pharmacokinetic (PBPK) model for p-tert-octylphenol (OP) for understanding the qualitative and quantitative determinants of its kinetics in Sprague-Dawley rats. Compartments of the PBPK model included the liver, richly perfused tissues, poorly perfused tissues, reproductive tissues, adipose tissue and subcutaneous space, in which OP uptake was described as a blood flow- or a membrane diffusion-limited process. The PBPK model successfully simulated previously published data on blood and tissue OP concentrations in Sprague-Dawley rats following oral, intravenous (i.v.) or subcutaneous (s.c.) routes. The model predicted that OP concentrations would reach 6.8, 13.8 and 27.9 ng ml(-1) (male) and 7.2, 14.7 and 31.4 ng ml(-1) (female), 4 h after a single i.v. dose of 2, 4 and 8 mg kg(-1), respectively. The model also predicted that OP concentrations would reach 53.3, 134.8 and 271.2 ng ml(-1) (male) and 87.4, 221.4 and 449.7 ng ml(-1) (female) 4 h after a single oral dose (50, 125 and 250 mg kg(-1)) and that, 4 h after a single s.c. dose (125 mg kg(-1)), OP concentrations would reach 111.3 ng ml(-1) (male) and 121.6 ng ml(-1). A marked sex difference was seen in blood and tissue OP concentrations. This was reflected in the model by a gender-specific maximal velocity of metabolism (V(max)) that was higher (1.77 x) in male than in female rats. Further studies are required to elucidate the mechanism underlying the gender differences and to evaluate whether that is also observed in humans.
Collapse
Affiliation(s)
- G Hamelin
- Département de santé environnementale et santé au travail, Université de Montréal, Montréal, Québec, Canada
| | | | | | | |
Collapse
|
23
|
Watanabe KH, Li Z, Kroll KJ, Villeneuve DL, Garcia-Reyero N, Orlando EF, Sepúlveda MS, Collette TW, Ekman DR, Ankley GT, Denslow ND. A Computational Model of the Hypothalamic-Pituitary-Gonadal Axis in Male Fathead Minnows Exposed to 17α-Ethinylestradiol and 17β-Estradiol. Toxicol Sci 2009; 109:180-92. [DOI: 10.1093/toxsci/kfp069] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
24
|
Harris LA, Barton HA. Comparing single and repeated dosimetry data for perfluorooctane sulfonate in rats. Toxicol Lett 2008; 181:148-56. [PMID: 18706985 DOI: 10.1016/j.toxlet.2008.07.014] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2008] [Revised: 07/10/2008] [Accepted: 07/10/2008] [Indexed: 11/19/2022]
Abstract
Perfluorooctane sulfonate (PFOS) is a member of a class of perfluorinated chemicals used in a variety of consumer and industrial applications because of their oleophobic and hydrophobic properties. It has been shown to cause toxicity in adult and developing laboratory animals. Because PFOS has also been shown to be widely distributed throughout the environment, there have been concerns about its potential health risk to humans. Limited pharmacokinetic data for PFOS are available in rodents and humans, while epidemiological studies of workers and extensive toxicity studies in rodents have been performed. The existing pharmacokinetic and toxicity database in rodents can be useful in the cross-species extrapolations needed to evaluate and interpret internal dosimetry in humans. A mathematical model that describes the disposition of PFOS in adult rats following intravenous, oral, and chronic dietary exposures was developed to gain a better understanding of the pharmacokinetics of PFOS and to determine whether single-dose kinetics are predictive of repeated-dose kinetics. In order to characterize existing time-course data, time-dependent and concentration-dependent changes in the pharmacokinetic parameters for urinary and biliary clearance and liver distribution were needed. Whether these time-dependent changes represent inconsistencies across experiments, effects of aging in the rats, or chemically induced changes in pharmacokinetics remains to be determined.
Collapse
Affiliation(s)
- Leona A Harris
- Department of Mathematics and Statistics, The College of New Jersey, Ewing, NJ 08628, USA.
| | | |
Collapse
|
25
|
Dekant W, Völkel W. Human exposure to bisphenol A by biomonitoring: Methods, results and assessment of environmental exposures. Toxicol Appl Pharmacol 2008; 228:114-34. [DOI: 10.1016/j.taap.2007.12.008] [Citation(s) in RCA: 346] [Impact Index Per Article: 21.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2007] [Revised: 11/27/2007] [Accepted: 12/02/2007] [Indexed: 11/29/2022]
|
26
|
Wetherill YB, Akingbemi BT, Kanno J, McLachlan JA, Nadal A, Sonnenschein C, Watson CS, Zoeller RT, Belcher SM. In vitro molecular mechanisms of bisphenol A action. Reprod Toxicol 2007; 24:178-98. [PMID: 17628395 DOI: 10.1016/j.reprotox.2007.05.010] [Citation(s) in RCA: 633] [Impact Index Per Article: 37.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2007] [Accepted: 05/18/2007] [Indexed: 11/29/2022]
Abstract
Bisphenol A (BPA, 2,2-bis (4-hydroxyphenyl) propane; CAS# 80-05-7) is a chemical used primarily in the manufacture of polycarbonate plastic, epoxy resins and as a non-polymer additive to other plastics. Recent evidence has demonstrated that human and wildlife populations are exposed to levels of BPA which cause adverse reproductive and developmental effects in a number of different wildlife species and laboratory animal models. However, there are major uncertainties surrounding the spectrum of BPA's mechanisms of action, the tissue-specific impacts of exposures, and the critical windows of susceptibility during which target tissues are sensitive to BPA exposures. As a foundation to address some of those uncertainties, this review was prepared by the "In vitro" expert sub-panel assembled during the "Bisphenol A: An Examination of the Relevance of Ecological, In vitro and Laboratory Animal Studies for Assessing Risks to Human Health" workshop held in Chapel Hill, NC, Nov 28-29, 2006. The specific charge of this expert panel was to review and assess the strength of the published literature pertaining to the mechanisms of BPA action. The resulting document is a detailed review of published studies that have focused on the mechanistic basis of BPA action in diverse experimental models and an assessment of the strength of the evidence regarding the published BPA research.
Collapse
Affiliation(s)
- Yelena B Wetherill
- Department of Environmental Health, Harvard School of Public Health, Boston, MA 02115, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Teeguarden JG, Hinderliter PM, Orr G, Thrall BD, Pounds JG. Particokinetics In Vitro: Dosimetry Considerations for In Vitro Nanoparticle Toxicity Assessments. Toxicol Sci 2006; 95:300-12. [PMID: 17098817 DOI: 10.1093/toxsci/kfl165] [Citation(s) in RCA: 501] [Impact Index Per Article: 27.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
The rapid growth in the use of in vitro methods for nanoparticle toxicity assessment has proceeded with limited consideration of the unique kinetics of these materials in solution. Particles in general and nanoparticles specifically, diffuse, settle, and agglomerate in cell culture media as a function of systemic and particle properties: media density and viscosity and particle size, shape, charge and density, for example. Cellular dose then is also a function of these factors as they determine the rate of transport of nanoparticles to cells in culture. Here we develop and apply the principles of dosimetry in vitro and outline an approach for simulation of nanoparticle particokinetics in cell culture systems. We illustrate that where equal mass concentrations (mug/ml) imply equal doses for dissimilar materials, the corresponding particle number or surface area concentration doses differ by orders of magnitude. More importantly, when rates of diffusional and gravitational particle delivery are accounted for, trends and magnitude of the cellular dose as a function of particle size and density differ significantly from those implied by "concentration" doses. For example, 15-nm silver nanoparticles appear approximately 4000 times more potent than micron-sized cadmium oxide particles on a cm(2)/ml media basis, but are only approximately 50 times more potent when differences in delivery to adherent cells are considered. We conclude that simple surrogates of dose can cause significant misinterpretation of response and uptake data for nanoparticles in vitro. Incorporating particokinetics and principles of dosimetry would significantly improve the basis for nanoparticle toxicity assessment, increasing the predictive power and scalability of such assays.
Collapse
|
28
|
Barton HA, Pastoor TP, Baetcke K, Chambers JE, Diliberto J, Doerrer NG, Driver JH, Hastings CE, Iyengar S, Krieger R, Stahl B, Timchalk C. The acquisition and application of absorption, distribution, metabolism, and excretion (ADME) data in agricultural chemical safety assessments. Crit Rev Toxicol 2006; 36:9-35. [PMID: 16708693 DOI: 10.1080/10408440500534362] [Citation(s) in RCA: 94] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
A proposal has been developed by the Agricultural Chemical Safety Assessment (ACSA) Technical Committee of the ILSI Health and Environmental Sciences Institute (HESI) for an improved approach to assessing the safety of crop protection chemicals. The goal is to ensure that studies are scientifically appropriate and necessary without being redundant, and that tests emphasize toxicological endpoints and exposure durations that are relevant for risk assessment. Incorporation of pharmacokinetic studies describing absorption, distribution, metabolism, and excretion is an essential tool for improving the design and interpretation of toxicity studies and their application for safety assessment. A tiered approach is described in which basic pharmacokinetic studies, similar to those for pharmaceuticals, are conducted for regulatory submission. Subsequent tiers provide additional information in an iterative manner, depending on pharmacokinetic properties, toxicity study results, and the intended uses of the compound.
Collapse
Affiliation(s)
- Hugh A Barton
- U.S. Environmental Protection Agency, National Centerfor Computational Toxicology, Research Triangle Park, North Carolina, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Heringa MB, Hogevonder C, Busser F, Hermens JLM. Measurement of the free concentration of octylphenol in biological samples with negligible depletion-solid phase microextraction (nd-SPME): Analysis of matrix effects. J Chromatogr B Analyt Technol Biomed Life Sci 2006; 834:35-41. [PMID: 16513434 DOI: 10.1016/j.jchromb.2006.02.009] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2004] [Revised: 01/31/2006] [Accepted: 02/04/2006] [Indexed: 11/22/2022]
Abstract
A negligible depletion-solid phase microextraction (nd-SPME) method is presented to measure free concentrations of octylphenol in biological samples. Potential confounding factors, such as matrix effects, are studied as well. Fouling of the fibre appears to occur, but it does not seem to reduce or enhance the measured uptake of octylphenol. In the setup applied here, without any agitation, it has also been found that there is a large effect of protein presence on the kinetics of octylphenol uptake. In addition, an apparent affinity constant of octylphenol for bovine serum albumin was determined.
Collapse
Affiliation(s)
- Minne B Heringa
- Institute of Risk Assessment Sciences, IRAS, Utrecht University, P.O. Box 80176, 3508 TD Utrecht, The Netherlands.
| | | | | | | |
Collapse
|
30
|
Schlosser PM, Borghoff SJ, Coldham NG, David JA, Ghosh SK. Physiologically-based pharmacokinetic modeling of genistein in rats, Part I: Model development. RISK ANALYSIS : AN OFFICIAL PUBLICATION OF THE SOCIETY FOR RISK ANALYSIS 2006; 26:483-500. [PMID: 16573635 DOI: 10.1111/j.1539-6924.2006.00743.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/08/2023]
Abstract
Genistein is a phytoestrogen-a plant-derived compound that binds to and activates the estrogen receptor-occurring at high levels in soy beans and food products, leading to widespread human exposure. The numerous scientific publications available describing genistein's dosimetry, mechanisms of action, and identified or putative health effects in both experimental animals and humans make it ideal for examination as an example of endocrine-active compound (EAC). We developed a physiologically-based pharmacokinetic (PBPK) model to quantify the internal, target-tissue dosimetry of genistein in adult rats. Complexities of the model include enterohepatic circulation, binding of both genistein and its conjugates to plasma proteins, and the multiple compartments used to describe transport through the bile duct and gastrointestinal tract. Other aspects of the model are simple perfusion-limited transport to the tissue groups and first-order rates of metabolism, uptake, and excretion. We describe here the model structure and initial calibration of the model by fitting to a large data set for Wistar rats. The model structure can be readily extrapolated to describe genistein dosimetry in humans or modified to describe the dosimetry of other phytoestrogens and phenolic EACs. The model does a fair job of capturing the pharmacokinetics. Although it does not describe the interindividual variability and we have not identified a single set of parameters that provide a good fit to the data for both oral and intravenous exposures, we believe it provides a good initial attempt at PBPK modeling for genistein, which can serve as a template for other phytoestrogens and in the design of future experiments and research that can be used to fill data gaps and better estimate model parameters.
Collapse
Affiliation(s)
- Paul M Schlosser
- CIIT Centers for Health Research, Research Triangle Park, NC 27711, USA.
| | | | | | | | | |
Collapse
|
31
|
Barton HA. Computational pharmacokinetics during developmental windows of susceptibility. JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH. PART A 2005; 68:889-900. [PMID: 16020183 DOI: 10.1080/15287390590912180] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/03/2023]
Abstract
Computational modeling has an increasing role in analyses of biological effects, including how the body handles chemicals (i.e., pharmacokinetics or toxicokinetics) and how the body responds to chemicals (i.e., pharmacodynamics or toxicodynamics). Pharmacokinetic models increasingly describe not just adult humans and animals, but also changes with age and life stage (e.g., pregnancy and fetal exposures, lactational exposures, and childhood growth). Physiologically based pharmacokinetic models provide an important route to estimate the potential changes in internal dose that may occur throughout the life cycle. These models require inputs describing changes in physiology, metabolism, and exposure with age and life stage. A particular challenge exists when the "equivalent" developmental period in the rodents and humans differs (e.g., early postnatal in rats and in utero in humans) such that the "equivalent" window of susceptibility to toxic effects of the chemical may involve substantially different exposures (e.g., lactational versus placental transfer). Pharmacodynamic modeling could similarly address changes with age, but few such models currently exist. The growth of systems biology is anticipated to change this over the coming decade.
Collapse
Affiliation(s)
- Hugh A Barton
- U.S. Environmental Protection Agency, Research Triangle Park, North Carolina, USA.
| |
Collapse
|
32
|
Teeguarden JG, Waechter JM, Clewell HJ, Covington TR, Barton HA. Evaluation of Oral and Intravenous Route Pharmacokinetics, Plasma Protein Binding, and Uterine Tissue Dose Metrics of Bisphenol A: A Physiologically Based Pharmacokinetic Approach. Toxicol Sci 2005; 85:823-38. [PMID: 15746009 DOI: 10.1093/toxsci/kfi135] [Citation(s) in RCA: 118] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Bisphenol A (BPA) is a weakly estrogenic monomer used in the production of polycarbonate plastic and epoxy resins, both of which are used in food contact and other applications. A physiologically based pharmacokinetic (PBPK) model of BPA pharmacokinetics in rats and humans was developed to provide a physiological context in which the processes controlling BPA pharmacokinetics (e.g., plasma protein binding, enterohepatic recirculation of the glucuronide [BPAG]) could be incorporated. A uterine tissue compartment was included to allow the correlation of simulated estrogen receptor (ER) binding of BPA with increases in uterine wet weight (UWW) in rats. Intravenous- and oral-route blood kinetics of BPA in rats and oral-route plasma and urinary elimination kinetics in humans were well described by the model. Simulations of rat oral-route BPAG pharmacokinetics were less exact, most likely the result of oversimplification of the GI tract compartment. Comparison of metabolic clearance rates derived from fitting rat i.v. and oral-route data implied that intestinal glucuronidation of BPA is significant. In rats, but not humans, terminal elimination rates were strongly influenced by enterohepatic recirculation. In the absence of BPA binding to plasma proteins, simulations showed high ER occupancy at doses without uterine effects. Restricting free BPA to the measured unbound amount demonstrated the importance of including plasma binding in BPA kinetic models: the modeled relationship between ER occupancy and UWW increases was consistent with expectations for a receptor-mediated response with low ER occupancy at doses with no response and increasing occupancy with larger increases in UWW.
Collapse
Affiliation(s)
- Justin G Teeguarden
- Biological Monitoring and Modeling, Pacific Northwest National Laboratory, 902 Battelle Boulevard, P7-56, Richland, Washington 99352, USA.
| | | | | | | | | |
Collapse
|
33
|
Clark LH, Setzer RW, Barton HA. Framework for evaluation of physiologically-based pharmacokinetic models for use in safety or risk assessment. RISK ANALYSIS : AN OFFICIAL PUBLICATION OF THE SOCIETY FOR RISK ANALYSIS 2004; 24:1697-1717. [PMID: 15660623 DOI: 10.1111/j.0272-4332.2004.00561.x] [Citation(s) in RCA: 55] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
Abstract
Proposed applications of increasingly sophisticated biologically-based computational models, such as physiologically-based pharmacokinetic models, raise the issue of how to evaluate whether the models are adequate for proposed uses, including safety or risk assessment. A six-step process for model evaluation is described. It relies on multidisciplinary expertise to address the biological, toxicological, mathematical, statistical, and risk assessment aspects of the modeling and its application. The first step is to have a clear definition of the purpose(s) of the model in the particular assessment; this provides critical perspectives on all subsequent steps. The second step is to evaluate the biological characterization described by the model structure based on the intended uses of the model and available information on the compound being modeled or related compounds. The next two steps review the mathematical equations used to describe the biology and their implementation in an appropriate computer program. At this point, the values selected for the model parameters (i.e., model calibration) must be evaluated. Thus, the fifth step is a combination of evaluating the model parameterization and calibration against data and evaluating the uncertainty in the model outputs. The final step is to evaluate specialized analyses that were done using the model, such as modeling of population distributions of parameters leading to population estimates for model outcomes or inclusion of early pharmacodynamic events. The process also helps to define the kinds of documentation that would be needed for a model to facilitate its evaluation and implementation.
Collapse
Affiliation(s)
- Leona H Clark
- U.S. Environmental Protection Agency, Office of Research and Development, National Health and Environmental Effects Research Laboratory, Experimental Toxicology Division, Research Triangle Park, NC 27711, USA
| | | | | |
Collapse
|